Astrana Health Reports Record Q4 2025 Earnings and Strong Outlook
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2 days ago
0mins
Should l Buy ASTH?
Source: seekingalpha
- Significant Revenue Growth: Astrana Health reported Q4 2025 revenue of $950.5 million, a 43% year-over-year increase, reflecting the full contribution from Prospect and continued organic growth in the Care Partners segment, showcasing the company's strong performance in the value-based care market.
- Outstanding Annual Performance: Total revenue for 2025 reached $3.2 billion, representing a 56% year-over-year growth and at the high end of the company's guidance range, indicating Astrana's competitive strength and growth potential, with expectations for 2026 revenue between $3.8 billion and $4.1 billion.
- Risk Management Strategy: Management anticipates that by Q1 2026, approximately 80% of revenue and over 36% of membership will be in full-risk arrangements, demonstrating the company's strategic positioning in risk management and market adaptability.
- Shareholder Return Plan: The company announced a repurchase of approximately 634,000 shares at an average price of $22.23 and increased the repurchase program from $50 million to $100 million, reflecting a commitment to shareholders and confidence in future growth.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ASTH?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ASTH
Wall Street analysts forecast ASTH stock price to rise
8 Analyst Rating
6 Buy
2 Hold
0 Sell
Strong Buy
Current: 24.510
Low
26.00
Averages
33.20
High
40.00
Current: 24.510
Low
26.00
Averages
33.20
High
40.00
About ASTH
Astrana Health, Inc. is a physician-centric, artificial intelligence (AI)-powered healthcare company focused on delivering patient-centered care. The Company provides care coordination services to each major constituent of the healthcare delivery system, including patients, families, primary care physicians, specialists, acute care hospitals, alternative sites of inpatient care, physician groups, and health plans. The Company's segments include Care Partners, Care Delivery, and Care Enablement. Its Care Partners segment is focused on building and managing provider networks by partnering with, empowering, and investing in provider partners aligned on a shared vision for coordinated care delivery. Its Care Delivery organization includes primary care, multi-specialty care, and ancillary care services. Its Care Enablement segment represents a comprehensive platform that integrates clinical, operational, financial, and administrative information. It supports more than 20,000 providers.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Astrana Health to Participate in Upcoming Investor Conferences
- Investor Conference Participation: Astrana Health is set to participate in upcoming investor conferences to showcase its innovations and technological capabilities in the healthcare sector, aiming to attract more investor interest in its business growth.
- Technology-Driven Healthcare Model: The company supports over 20,000 providers and 1.6 million patients through its AI-powered platform, driving value-based care arrangements that enhance patient experiences and outcomes.
- Physician-Centric Services: Astrana Health is committed to building a scalable care delivery infrastructure from the physician's perspective, ensuring high-quality, patient-centered care that enhances the overall value of the healthcare system.
- Vision for Future Development: The company's goal is to create a better healthcare system by integrating primary, specialty, and ancillary care, aiming for improved care, experiences, and outcomes while promoting sustainable industry growth.
See More
Astrana Health to Participate in Multiple Upcoming Investor Conferences
- Investor Conference Schedule: Astrana Health will participate in the TD Cowen 45th Annual Health Care Conference in Boston on March 4, 2026, featuring a fireside chat at 9:10am ET, showcasing the company's innovative capabilities in healthcare.
- Value-Based Summit: The company will also attend the Jefferies Value-Based Healthcare Summit in Miami on March 9, 2026, with a fireside chat at 11am ET, further emphasizing its leadership in value-based care.
- Global Healthcare Conference: Astrana will participate in the Barclays 28th Annual Global Healthcare Conference in Miami on March 10-11, 2026, with a fireside chat on March 11, providing investors with in-depth analysis of company strategy and market outlook.
- Virtual Forum Participation: Additionally, Astrana will engage in the KeyBanc Capital Markets Healthcare Forum on March 17, 2026, and the Oppenheimer 36th Annual MedTech & Services Conference on March 18, 2026, demonstrating its ongoing innovation and market adaptability in the healthcare technology sector.
See More
U.S. Stocks Mixed as Fear Index Shows Slight Easing
- Fear Index Update: The CNN Money Fear & Greed Index registered at 41.6 on Monday, indicating a slight increase but remaining in the 'Fear' zone, which suggests continued cautious market sentiment that could exert downward pressure on stock prices.
- Mixed Market Performance: The Dow Jones fell approximately 73 points to close at 48,904.78, while the S&P 500 edged up 0.04% to 6,881.62, reflecting a divergence in sector performance, particularly with consumer staples and healthcare stocks facing significant losses.
- Manufacturing Data Decline: The ISM manufacturing PMI decreased from 52.6 to 52.4, although this was above market expectations of 51.8, indicating a moderate slowdown in manufacturing activity that may impact investor confidence moving forward.
- Middle East Tensions: President Trump defended 'Operation Epic Fury' during a White House briefing, aiming to dismantle Iran's military capabilities within a four to five-week timeline, yet the escalating tensions could heighten investor anxiety and market volatility.
See More
ASTH Stock 52-Week Highs and Lows Analysis
- Price Fluctuation Analysis: ASTH's 52-week low is $18.08 per share, while the high is $34.80, with the last trade at $25.27, indicating the stock's price volatility and reflecting market interest and investor sentiment changes.
- Market Trend Observation: The current price of $25.27 is close to the 52-week median, suggesting a potential recovery in investor confidence, particularly after significant fluctuations, which may attract more investor attention.
- Technical Indicator Reference: ASTH's stock price has crossed above its 200-day moving average, potentially signaling a short-term upward trend, prompting investors to monitor this technical signal for future investment opportunities.
- Investor Sentiment Assessment: Although the current stock price is below the 52-week high, it remains above the low, indicating market recognition of ASTH's potential value, leading investors to seek buying opportunities within this price range.
See More
Astrana Health Reports Record Q4 2025 Earnings and Strong Outlook
- Significant Revenue Growth: Astrana Health reported Q4 2025 revenue of $950.5 million, a 43% year-over-year increase, reflecting the full contribution from Prospect and continued organic growth in the Care Partners segment, showcasing the company's strong performance in the value-based care market.
- Outstanding Annual Performance: Total revenue for 2025 reached $3.2 billion, representing a 56% year-over-year growth and at the high end of the company's guidance range, indicating Astrana's competitive strength and growth potential, with expectations for 2026 revenue between $3.8 billion and $4.1 billion.
- Risk Management Strategy: Management anticipates that by Q1 2026, approximately 80% of revenue and over 36% of membership will be in full-risk arrangements, demonstrating the company's strategic positioning in risk management and market adaptability.
- Shareholder Return Plan: The company announced a repurchase of approximately 634,000 shares at an average price of $22.23 and increased the repurchase program from $50 million to $100 million, reflecting a commitment to shareholders and confidence in future growth.
See More
U.S. Stocks Mixed Amid Iran-U.S. Conflict; Energy Shares Rise
- Mixed Market Performance: U.S. stocks exhibited mixed performance amid the ongoing Iran-U.S. conflict, with the Dow Jones index falling 0.1% to 48,929.19 while the NASDAQ gained 0.37% to 22,751.80, indicating a complex market sentiment.
- Energy Sector Gains: Energy shares rose by 1.8% on Monday, reflecting optimistic expectations for energy demand despite the overall mixed market performance, suggesting strong investor confidence in the energy sector.
- Sealed Air Earnings Beat: Sealed Air Corp (NYSE:SEE) reported fourth-quarter earnings of 77 cents per share, exceeding analyst expectations of 73 cents, with quarterly sales reaching $1.401 billion, surpassing the forecast of $1.342 billion, demonstrating the company's robust profitability.
- International Market Fluctuations: European markets declined broadly, with the STOXX 600 falling 1.65%, reflecting global economic uncertainties, while Asian markets mostly closed lower, indicating investor concerns about future economic prospects.
See More
Astrana Health to Participate in Upcoming Investor Conferences
- Investor Conference Participation: Astrana Health is set to participate in upcoming investor conferences to showcase its innovations and technological capabilities in the healthcare sector, aiming to attract more investor interest in its business growth.
- Technology-Driven Healthcare Model: The company supports over 20,000 providers and 1.6 million patients through its AI-powered platform, driving value-based care arrangements that enhance patient experiences and outcomes.
- Physician-Centric Services: Astrana Health is committed to building a scalable care delivery infrastructure from the physician's perspective, ensuring high-quality, patient-centered care that enhances the overall value of the healthcare system.
- Vision for Future Development: The company's goal is to create a better healthcare system by integrating primary, specialty, and ancillary care, aiming for improved care, experiences, and outcomes while promoting sustainable industry growth.
See More
Astrana Health to Participate in Multiple Upcoming Investor Conferences
- Investor Conference Schedule: Astrana Health will participate in the TD Cowen 45th Annual Health Care Conference in Boston on March 4, 2026, featuring a fireside chat at 9:10am ET, showcasing the company's innovative capabilities in healthcare.
- Value-Based Summit: The company will also attend the Jefferies Value-Based Healthcare Summit in Miami on March 9, 2026, with a fireside chat at 11am ET, further emphasizing its leadership in value-based care.
- Global Healthcare Conference: Astrana will participate in the Barclays 28th Annual Global Healthcare Conference in Miami on March 10-11, 2026, with a fireside chat on March 11, providing investors with in-depth analysis of company strategy and market outlook.
- Virtual Forum Participation: Additionally, Astrana will engage in the KeyBanc Capital Markets Healthcare Forum on March 17, 2026, and the Oppenheimer 36th Annual MedTech & Services Conference on March 18, 2026, demonstrating its ongoing innovation and market adaptability in the healthcare technology sector.
See More
U.S. Stocks Mixed as Fear Index Shows Slight Easing
- Fear Index Update: The CNN Money Fear & Greed Index registered at 41.6 on Monday, indicating a slight increase but remaining in the 'Fear' zone, which suggests continued cautious market sentiment that could exert downward pressure on stock prices.
- Mixed Market Performance: The Dow Jones fell approximately 73 points to close at 48,904.78, while the S&P 500 edged up 0.04% to 6,881.62, reflecting a divergence in sector performance, particularly with consumer staples and healthcare stocks facing significant losses.
- Manufacturing Data Decline: The ISM manufacturing PMI decreased from 52.6 to 52.4, although this was above market expectations of 51.8, indicating a moderate slowdown in manufacturing activity that may impact investor confidence moving forward.
- Middle East Tensions: President Trump defended 'Operation Epic Fury' during a White House briefing, aiming to dismantle Iran's military capabilities within a four to five-week timeline, yet the escalating tensions could heighten investor anxiety and market volatility.
See More
ASTH Stock 52-Week Highs and Lows Analysis
- Price Fluctuation Analysis: ASTH's 52-week low is $18.08 per share, while the high is $34.80, with the last trade at $25.27, indicating the stock's price volatility and reflecting market interest and investor sentiment changes.
- Market Trend Observation: The current price of $25.27 is close to the 52-week median, suggesting a potential recovery in investor confidence, particularly after significant fluctuations, which may attract more investor attention.
- Technical Indicator Reference: ASTH's stock price has crossed above its 200-day moving average, potentially signaling a short-term upward trend, prompting investors to monitor this technical signal for future investment opportunities.
- Investor Sentiment Assessment: Although the current stock price is below the 52-week high, it remains above the low, indicating market recognition of ASTH's potential value, leading investors to seek buying opportunities within this price range.
See More
Astrana Health Reports Record Q4 2025 Earnings and Strong Outlook
- Significant Revenue Growth: Astrana Health reported Q4 2025 revenue of $950.5 million, a 43% year-over-year increase, reflecting the full contribution from Prospect and continued organic growth in the Care Partners segment, showcasing the company's strong performance in the value-based care market.
- Outstanding Annual Performance: Total revenue for 2025 reached $3.2 billion, representing a 56% year-over-year growth and at the high end of the company's guidance range, indicating Astrana's competitive strength and growth potential, with expectations for 2026 revenue between $3.8 billion and $4.1 billion.
- Risk Management Strategy: Management anticipates that by Q1 2026, approximately 80% of revenue and over 36% of membership will be in full-risk arrangements, demonstrating the company's strategic positioning in risk management and market adaptability.
- Shareholder Return Plan: The company announced a repurchase of approximately 634,000 shares at an average price of $22.23 and increased the repurchase program from $50 million to $100 million, reflecting a commitment to shareholders and confidence in future growth.
See More
U.S. Stocks Mixed Amid Iran-U.S. Conflict; Energy Shares Rise
- Mixed Market Performance: U.S. stocks exhibited mixed performance amid the ongoing Iran-U.S. conflict, with the Dow Jones index falling 0.1% to 48,929.19 while the NASDAQ gained 0.37% to 22,751.80, indicating a complex market sentiment.
- Energy Sector Gains: Energy shares rose by 1.8% on Monday, reflecting optimistic expectations for energy demand despite the overall mixed market performance, suggesting strong investor confidence in the energy sector.
- Sealed Air Earnings Beat: Sealed Air Corp (NYSE:SEE) reported fourth-quarter earnings of 77 cents per share, exceeding analyst expectations of 73 cents, with quarterly sales reaching $1.401 billion, surpassing the forecast of $1.342 billion, demonstrating the company's robust profitability.
- International Market Fluctuations: European markets declined broadly, with the STOXX 600 falling 1.65%, reflecting global economic uncertainties, while Asian markets mostly closed lower, indicating investor concerns about future economic prospects.
See More
